Autoimmune Blistering Diseases in the Elderly
Özet
Referanslar
OECD (2024), Elderly population (indicator). doi: 10.1787/8d805ea1-en (Accessed on 25 March 2024)
Rudnicka, E., Napierała, P., Podfigurna, A., Męczekalski, B., Smolarczyk, R., & Grymowicz, M. (2020). The World Health Organization (WHO) approach to healthy ageing. Maturitas, 139, 6–11.
Zhu, C., Gabrielli, S., Khoury, L., Osman, M., Litvinov, I. V., Iannattone, L., Lefrançois, P., & Netchiporouk, E. (2023). Immunosenescence, Inflammaging, and Dermatology: Insights and Opportunities. Journal of cutaneous medicine and surgery, 27(5), 532– 534.
Moro, F., Fania, L., Sinagra, J. L. M., Salemme, A., & Di Zenzo, G. (2020). Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules, 10(10), 1432.
Boismal, F., Serror, K., Dobos, G., Zuelgaray, E., Bensussan, A., & Michel, L. (2020). Vieillissement cutané - Physiopathologie et thérapies innovantes [Skin aging: Pathophysiology and innovative therapies]. Medecine sciences : M/S, 36(12), 1163– 1172.
Kim, M., Borradori, L., & Murrell, D. F. (2016). Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management. Drugs & aging, 33(10), 711–723.
Parker, S. R., & MacKelfresh, J. (2011). Autoimmune blistering diseases in the elderly. Clinics in dermatology, 29(1), 69–79.
Luo, D. Q., Huang, M. X., Liu, J. H., Tang, W., Zhao, Y. K., & Sarkar, R. (2016). Bullous Scabies. The American journal of tropical medicine and hygiene, 95(3), 689– 693.
Rosi-Schumacher, M., Baker, J., Waris, J., Seiffert-Sinha, K., & Sinha, A. A. (2023). Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Frontiers in immunology, 14, 1159351.
Kridin, K., & Ludwig, R. J. (2018). The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations. Frontiers in medicine, 5, 220.
Chen, X., Zhang, Y., Luo, Z., Wu, Y., Niu, T., Zheng, J., & Xie, Y. (2022). Prognostic factors for mortality in bullous pemphigoid: A systematic review and metaanalysis. PloS one, 17(4), e0264705.
Tsuji-Abe, Y., Akiyama, M., Yamanaka, Y., Kikuchi, T., Sato-Matsumura, K. C., & Shimizu, H. (2005). Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. Journal of dermatological science, 37(3), 145–149.
Lo Schiavo, A., Ruocco, E., Brancaccio, G., Caccavale, S., Ruocco, V., & Wolf, R. (2013). Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clinics in dermatology, 31(4), 391–399.
Lamberts, A., Meijer, J. M., & Jonkman, M. F. (2018). Nonbullous pemphigoid: A systematic review. Journal of the American Academy of Dermatology, 78(5), 989– 995.e2.
Schmidt, E., & Zillikens, D. (2013). Pemphigoid diseases. Lancet (London, England), 381(9863), 320–332.
Farnaghi, F., Ehsani, A. H., Kamyab-Hesary, K., Abbasian, S., Seirafi, H., & Nasimi, M. (2020). Correlation of dermal and blood eosinophilia with bullous pemphigoid disease severity. International journal of women's dermatology, 6(3), 171–175.
Harano, Y., Mitamura, Y., Jiang, P., Fujita, T., & Babazono, A. (2023). Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database. Journal of diabetes investigation, 14(6), 756–766.
Maronese, C. A., Caproni, M., Moltrasio, C., Genovese, G., Vezzoli, P., Sena, P., Previtali, G., Cozzani, E., Gasparini, G., Parodi, A., Atzori, L., Antiga, E., Maglie, R.,
Moro, F., Mariotti, E. B., Corrà, A., Pallotta, S., Didona, B., Marzano, A. V., & Di Zenzo, G. (2022). Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study. Frontiers in medicine, 9, 841506.
Langan, S. M., Groves, R. W., & West, J. (2011). The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. The Journal of investigative dermatology, 131(3), 631–636.
Borradori, L., Van Beek,… Joly, P. (2022). Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology : JEADV, 36(10), 1689–1704.
Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138: 370–79.
Schmidt, E., Rashid, H., Marzano, A. V., et al. (2021). European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. Journal of the European Academy of Dermatology and Venereology : JEADV, 35(10), 1926–1948.
Du, G., Patzelt, S., van Beek, N., & Schmidt, E. (2022). Mucous membrane pemphigoid. Autoimmunity reviews, 21(4), 103036.
Kridin, K., & Schmidt, E. (2021). Epidemiology of Pemphigus. JID innovations : skin science from molecules to population health, 1(1), 100004.
Kim, J. H., & Kim, S. C. (2019). Paraneoplastic Pemphigus: Paraneoplastic Autoimmune Disease of the Skin and Mucosa. Frontiers in immunology, 10, 1259.
Antiga, E., Bech, R., Maglie, R., et al.. (2023). S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated
by the European Academy of Dermatology and Venereology (EADV). Journal of the European Academy of Dermatology and Venereology : JEADV, 37(6), 1118–1134.
Kridin, K., Kneiber, D., Kowalski, E. H., Valdebran, M., & Amber, K. T. (2019). Epidermolysis bullosa acquisita: A comprehensive review. Autoimmunity reviews, 18(8), 786–795.
Miyamoto, D., Gordilho, J. O., Santi, C. G., & Porro, A. M. (2022). Epidermolysis bullosa acquisita. Anais brasileiros de dermatologia, 97(4), 409–423.
